Bristol-Myers Squibb Company BMY
NYSE · Healthcare · Drug Manufacturers - General
$58.80
Close on Fri, 20 Nov 2026 · market value $120B
What the price is betting on
Below its recordAt $59, the price assumes revenue shrinks about 11% a year for five years, from $50B to about $31B by FY2030. That is about the same as what analysts expect for the next two years and less than the company's own last three years.
Revenue growth a year. The price figure comes from a reverse DCF at a 6.4% discount rate.
Track it and Parra checks each report against the path, and tells you when revenue falls behind it.
Own more than BMY? Check up to 5 of your stocks at once, free, no account.
Both sides
Three stories, three values
Bear
$73
Base
$81
Bull
$91
Today $59
- Bear $73. Cash flow grows -7% a year for the next 5 years, slower than expected, then slows to long-run growth.
- Base $81. Cash flow grows -5% a year for the next 5 years, the least the valuation takes, though analysts expect -9%, then slows to long-run growth.
- Bull $91. Cash flow grows -3% a year for the next 5 years, faster than expected, then slows to long-run growth.
Stories set by rules from the company’s record.
Checkpoints
The revenue the price needs
- YearNeedsAnalysts expect
- FY2026$48.6B$50.2B, on the path
- FY2027$43.5B$48.8B, on the path
- FY2028$38.8B$40.4B, on the path
- FY2029$34.7B$37.2B, on the path
- FY2030$31B$37.1B, on the path
Each year's revenue at −11% growth from $50B in the 12 months to September 2026.
At a glance
Healthcare · Drug Manufacturers - General · listed on NYSE
- Revenue, FY2025
- $48.2B
- Growth, 3 years a year
- 3.9%
- Cash margin
- 27%
- Net debt
- $36.5B
- Shares, 3-year change
- −4.9%
- Dividend yield
- 4.2%
What other healthcare prices are betting on
Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.